Last reviewed · How we verify
Oral dissolution therapy
At a glance
| Generic name | Oral dissolution therapy |
|---|---|
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- ARVI
- Nausea
- Dizziness
- ARI
- Rhinitis
- Somnolence
- Diarrhea
- Increased blood pressure
- Allergic dermatitis
- Abdominal pain
- Hypertensive crisis
Key clinical trials
- Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers (PHASE1)
- Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease (PHASE2)
- Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis (EARLY_PHASE1)
- Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer (PHASE1)
- Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI (PHASE1, PHASE2)
- Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia (PHASE3)
- The Efficacy of Oral Dissolution Therapy (ODT), Extracorporeal Shock Wave Lithotripsy (ESWL), and Combined ESWL and ODT as Non-Invasive Modalities for Treating Small and Medium-Sized Radiolucent Renal Stones (NA)
- Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral dissolution therapy CI brief — competitive landscape report
- Oral dissolution therapy updates RSS · CI watch RSS
- Cairo University portfolio CI